Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299466 | 0.91 | PPARG (0.59) | PPARGALDH1A1MAPTSMN1; SMN2PTPN1 | |
| SCHEMBL6298704 | 0.90 | PPARG (0.55) | PPARGALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6134699 | 0.87 | PPARG (0.47) | PPARGALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6298976 | 0.83 | KMO (0.43) | PPARGALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6301176 | 0.83 | KMO (0.43) | PPARGALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6301171 | 0.82 | KMO (0.42) | PPARGALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6492218 | 0.82 | PPARG (0.48) | PPARGPTPN1 | |
| SCHEMBL6493819 | 0.81 | PPARG (0.59) | PPARG | |
| SCHEMBL6299665 | 0.81 | PPARG (0.42) | PPARGALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL6299657 | 0.81 | PPARG (0.42) | PPARGALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | claimed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | claimed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | claimed |
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | PPARG 858/4885ALDH1A1 476/4885MAPT 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.